Cargando…

Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular Carcinoma

Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC). The present study was undertaken to determine whether the growth and metastasis of HCC were influenced in mice receiving sorafenib prior to implantation with tumors, and to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qiang-Bo, Sun, Hui-Chuan, Zhang, Ke-Zhi, Jia, Qing-An, Bu, Yang, Wang, Miao, Chai, Zong-Tao, Zhang, Quan-Bao, Wang, Wen-Quan, Kong, Ling-Qun, Zhu, Xiao-dong, Lu, Lu, Wu, Wei-Zhong, Wang, Lu, Tang, Zhao-You
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568028/ https://www.ncbi.nlm.nih.gov/pubmed/23409093 http://dx.doi.org/10.1371/journal.pone.0055945

Ejemplares similares

Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30
por: Guo, Zhigui, et al.
Publicado: (2016)

Aspirin Minimized the Pro-Metastasis Effect of Sorafenib and Improved Survival by Up-Regulating HTATIP2 in Hepatocellular Carcinoma
por: Lu, Lu, et al.
Publicado: (2013)

Arsenic trioxide induces differentiation of CD133(+) hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model
por: Zhang, Ke-Zhi, et al.
Publicado: (2014)

The Prometastatic Microenvironment of the Liver
por: Vidal-Vanaclocha, Fernando
Publicado: (2008)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Carbonic anhydrase XII mediates the survival and prometastatic functions of macrophages in human hepatocellular carcinoma
por: Ning, Wan-Ru, et al.
Publicado: (2022)

IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells
por: Magidey-Klein, Ksenia, et al.
Publicado: (2021)

Tanshinone IIA inhibits metastasis after palliative resection of hepatocellular carcinoma and prolongs survival in part via vascular normalization
por: Wang, Wen-Quan, et al.
Publicado: (2012)

Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy
por: Zheng, Jian-feng, et al.
Publicado: (2015)

LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells: LIMT contributes to sorafenib chemoresistance in HCC
por: Sun, Jing, et al.
Publicado: (2021)

CCDC25: precise navigator for neutrophil extracellular traps on the prometastatic road
por: Liu, Ruochen, et al.
Publicado: (2020)

The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib
por: Wang, Wen-Quan, et al.
Publicado: (2014)

The Clinical Significance of the CD163+ and CD68+ Macrophages in Patients with Hepatocellular Carcinoma
por: Kong, Ling-Qun, et al.
Publicado: (2013)

Bone Lesion‐Derived Extracellular Vesicles Fuel Prometastatic Cascades in Hepatocellular Carcinoma by Transferring ALKBH5‐Targeting miR‐3190‐5p
por: Han, Shenqi, et al.
Publicado: (2023)

Pleiotrophin drives a prometastatic immune niche in breast cancer
por: Ganguly, Debolina, et al.
Publicado: (2023)

Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapy
por: Karagiannis, George S., et al.
Publicado: (2022)

Sorafenib Monotherapy Versus Sorafenib Combined with Regional Therapies for Hepatocellular Carcinoma Patients with Pulmonary Oligometastases: A Propensity Score-matched Analysis
por: Chen, Jinbin, et al.
Publicado: (2018)

DJ-1/FGFR-1 Signaling Pathway Contributes to Sorafenib Resistance in Hepatocellular Carcinoma
por: Chen, Xin, et al.
Publicado: (2022)

MicroRNA-26a Inhibits Angiogenesis by Down-Regulating VEGFA through the PIK3C2α/Akt/HIF-1α Pathway in Hepatocellular Carcinoma
por: Chai, Zong-Tao, et al.
Publicado: (2013)

Ets2 anchors the prometastatic function of mutant p53 in osteosarcoma
por: Liu, Daniel D., et al.
Publicado: (2017)

Prometastatic Molecular Profiles in Breast Tumors From Socially Isolated Women
por: Bower, Julienne E, et al.
Publicado: (2018)

p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi
por: Tan, Xiaochao, et al.
Publicado: (2021)

Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function
por: Román-Fernández, Alvaro, et al.
Publicado: (2023)

ABHD12 contributes to tumorigenesis and sorafenib resistance by preventing ferroptosis in hepatocellular carcinoma
por: Cai, Mengxing, et al.
Publicado: (2023)

ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis
por: Lin, Qiushi, et al.
Publicado: (2019)

FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
por: Gao, Lixia, et al.
Publicado: (2017)

Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma
por: Li, Danyang, et al.
Publicado: (2022)

Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma
por: Kong, Fan-Hua, et al.
Publicado: (2021)

Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response
por: Zhang, Yingqiang, et al.
Publicado: (2015)

Mechanisms behind prometastatic changes induced by neoadjuvant chemotherapy in the breast cancer microenvironment
por: Perelmuter, Vladimir M, et al.
Publicado: (2019)

The prometastatic relevance of tumor‐infiltrating B lymphocytes in laryngeal squamous cell carcinoma
por: Missale, Francesco, et al.
Publicado: (2023)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma
por: Wu, Fei-Xiang, et al.
Publicado: (2017)

Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review
por: Hosseinzadeh, Faezeh, et al.
Publicado: (2018)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

Dendritic Cells Pulsed with Exosomes in Combination with PD-1 Antibody Increase the Efficacy of Sorafenib in Hepatocellular Carcinoma Model()()
por: Shi, Shengbin, et al.
Publicado: (2018)

Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy
por: Yao, Wang, et al.
Publicado: (2020)

Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
por: Lu, Haofeng, et al.
Publicado: (2022)

Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
por: Orive‐Ramos, Ana, et al.
Publicado: (2017)

Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome
por: Capaci, Valeria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qo48ftfblebn5aeore90srpqjb